Grifols (GIKLY) Total Non-Current Liabilities (2010 - 2025)

Grifols (GIKLY) reported Total Non-Current Liabilities of $11.7 billion for Q4 2025, up 3.27% on a YoY basis from $11.4 billion in Q4 2024, and up 3.27% quarter-over-quarter from $11.4 billion in Q4 2024.

Grifols (GIKLY) Total Non-Current Liabilities (2010 - 2025) Analysis & Trends

Grifols has reported Total Non-Current Liabilities for 16 years, with the latest figure at $11.7 billion in Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 3.27% year-over-year to $11.7 billion; the trailing twelve-month figure through Dec 2025 stood at $11.7 billion (up 3.27% YoY), and the FY2025 full-year result was $11.7 billion, up 20873.57% from the prior year.
  • Total Non-Current Liabilities for Q4 2025 stood at $11.7 billion, up from $11.4 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $12.0 billion in Q4 2023, with the low at $9.7 billion in Q4 2021.
  • Historically, Total Non-Current Liabilities has averaged $11.2 billion across 5 years, with a median of $11.5 billion in 2022.
  • Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 18.68% — and 2024, when it declined 5.22%.
  • Grifols' Total Non-Current Liabilities stood at $9.7 billion in 2021, then gained by 18.68% to $11.5 billion in 2022, then advanced by 4.7% to $12.0 billion in 2023, then slipped by 5.22% to $11.4 billion in 2024, then advanced by 3.27% to $11.7 billion in 2025.
  • The last three Total Non-Current Liabilities figures came in at $11.7 billion (Q4 2025), $11.4 billion (Q4 2024), and $12.0 billion (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -31.03 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 48.74 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 119.22 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 108.96 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 75.11 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 80.55 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 31.56 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 113.51 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 61.52 Bn
10 Grifols - - - 11.75 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 11.75 Bn
Dec 31, 2024 11.37 Bn
Dec 31, 2023 12.00 Bn
Dec 31, 2022 11.46 Bn
Dec 31, 2021 9.66 Bn
Dec 31, 2020 8.61 Bn
Sep 30, 2020 8.52 Bn
Mar 31, 2020 8.12 Bn
Dec 31, 2019 8.11 Bn
Sep 30, 2019 8.18 Bn
Mar 31, 2019 550,128.37
Dec 31, 2018 7.45 Bn
Sep 30, 2018 7.61 Bn
Jun 30, 2018 7.69 Bn
Mar 31, 2018 8.96 Bn
Dec 31, 2017 7.43 Bn
Jun 30, 2017 7.29 Bn
Mar 31, 2017 -289,790.68
Dec 31, 2016 5.75 Bn
Sep 30, 2016 5.70 Bn